









Markets
/
Stocks
/
nasdaq-pfe
/

Pfizer Inc

PFE

24.290USD

0.000

Close 10/30, 16:00（ET）Quotes delayed by 15 min

138.09BMarket Cap

12.84P/E TTM



Pfizer Inc

24.290

0.000

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Pfizer Inc

Currency: USD Updated: 2025-10-30

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pfizer Inc's Score

Industry at a Glance

Industry Ranking

59 / 159

Overall Ranking

163 / 4621

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 26 analysts

Buy

Current Rating

29.023

Target Price

+19.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pfizer Inc Highlights

StrengthsRisks

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 119.41%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 119.41%.

Fairly Valued

The company’s latest PE is 12.82, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.82B shares, decreasing 2.57% quarter-over-quarter.

Held by Irving Kahn

Star Investor Irving Kahn holds 730.99K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-30

The company's current financial score is 6.75, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 14.65B, representing a year-over-year increase of 10.31%, while its net profit experienced a year-over-year increase of 6997.56%.

Score

Industry at a Glance

Previous score

6.75

Change



Financials

6.55

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.73

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.47

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.12

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.90

Key Metrics

Free cash flow

No Data

Pfizer Inc's Company Valuation

Currency: USD Updated: 2025-10-30

The company’s current valuation score is 8.49, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 12.82, which is 517.73% below the recent high of 79.17 and 4103.27% above the recent low of -513.09.

Score

Industry at a Glance

Previous score

8.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 59/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-30

The company’s current earnings forecast score is 7.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Pfizer Inc is 29.00, with a high of 37.23 and a low of 24.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 26 analysts

Buy

Current Rating

29.023

Target Price

+19.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Pfizer Inc

PFE

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-30

The company’s current price momentum score is 6.46, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 26.60 and the support level at 23.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.46

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.153

Sell

RSI(14)

42.247

Neutral

STOCH(KDJ)(9,3,3)

26.687

Sell

ATR(14)

0.330

Low Volatility

CCI(14)

-90.977

Neutral

Williams %R

82.716

Oversold

TRIX(12,20)

-0.081

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

24.522

Sell

MA10

24.605

Sell

MA20

24.985

Sell

MA50

24.818

Sell

MA100

24.733

Sell

MA200

24.678

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-30

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 5.81. The latest institutional shareholding proportion is 67.19%, representing a quarter-over-quarter decrease of 0.82%. The largest institutional shareholder is The Vanguard, holding a total of 530.68M shares, representing 9.33% of shares outstanding, with 2.51% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

530.68M

+1.94%

State Street Investment Management (US)

296.30M

-0.23%

BlackRock Institutional Trust Company, N.A.

288.89M

-0.91%

Geode Capital Management, L.L.C.

127.47M

+1.45%

Norges Bank Investment Management (NBIM)

93.65M

+6.68%

Wellington Management Company, LLP

77.00M

-25.60%

State Farm Insurance Companies

57.59M

-0.27%

MFS Investment Management

72.76M

-0.38%

BlackRock Asset Management Ireland Limited

54.65M

+8.29%

Charles Schwab Investment Management, Inc.

49.17M

+2.36%

Risk Assessment

Currency: USD Updated: 2025-10-30

The company’s current risk assessment score is 9.32, which is higher than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.51. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.